Clinical trial · Interventional
Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer
Phase II Trial Of Combined Resection, Intraperitoneal Chemotherapy, And Whole Abdominal Radiation For Treatment Of Peritoneal Mesothelioma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs directly into the tumor after surgery and combining them with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining surgery, chemotherapy, and radiation therapy in treating patients who have peritoneal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Mesothelioma | Malignant Mesothelioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (8)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cisplatin | Drug | Cisplatin | ALIAS |
| conventional surgery | Procedure | — | UNRESOLVED |
| doxorubicin hydrochloride | Drug | Doxorubicin | ALIAS |
| gemcitabine hydrochloride | Drug | Gemcitabine | ALIAS |
| hyperthermia treatment | Procedure | — | UNRESOLVED |
| mitomycin C | Drug | Mitomycin | ALIAS |
| radiation therapy | Radiation | — | UNRESOLVED |
| recombinant interferon gamma | Biological | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed malignant mesothelioma * Measurable or evaluable disease * Ineligible for other high-priority study * No CNS metastases PATIENT CHARACTERISTICS: Age: * Over 18 Performance status: * SWOG 0-2 * Karnofsky 60-100% Life expectancy: * More than 2 months Hematopoietic: * WBC greater than 3,000/mm3 * Platelet count greater than 100,000/mm3 Hepatic: * Bilirubin less than 1.5 times normal Renal: * Creatinine clearance at least 45 mL/min * BUN less than 1.5 times normal * No significant calcium abnormalities Cardiovascular: * No symptomatic cardiovascular disease * No New York Heart Association class II, III, or IV heart disease * No congestive heart failure * No angina pectoris * No cardiac arrhythmia * No uncontrolled hypertension Other: * No significant phosphate, electrolyte, or other metabolic abnormalities (e.g., metabolic acidosis) * No uncontrolled psychiatric disorder or neurologic disease * No seizure disorder * No other malignancy within the past 5 years except curatively treated carcinoma in situ of the cervix or skin cancer * No other serious medical or psychiatric illness * No uncontrolled serious infection * No senility or emotional instability * Not pregnant or nursing * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * No more than 2 prior chemotherapy regimens * No more than 1 prior intraperitoneal chemotherapy regimen * More than 6 weeks since prior chemotherapy * No other concurrent chemotherapy Endocrine therapy: * No concurrent hormonal therapy except for nondisease-related conditions (e.g., insulin for diabetes) * Concurrent steroids for antiemesis, premedication, adrenal failure, or septic shock allowed Radiotherapy: * No prior abdominal, pelvic, or lower chest radiotherapy Surgery: * Prior surgical resection preceding disease recurrence allowed * More than 1 week since prior surgery
References
Publications (0)
Data not yet available